Altimmune

Altimmune focused on the development of products to stimulate robust and durable immune responses for the prevention.

Launch date

1997

Employees

Market cap

Enterprise valuation

$342m (Public information from Sep 2024)

Gaithersburg Maryland (HQ)

http://altimmune.com

https://www.facebook.com/pages/altimmune-inc/171736203175893 https://www.linkedin.com/company/altimmune/

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	8.2m	4.4m	(<1m)	<1m	31.3m	25.0m	1.0m
% growth	41 %	(46 %)	(102 %)	(726 %)	7236 %	(20 %)	(96 %)
EBITDA	(54.2m)	(85.7m)	(84.9m)	(75.5m)	(99.1m)	(110m)	(121m)
% EBITDA margin	(662 %)	(1943 %)	124856 %	(17727 %)	(317 %)	(441 %)	(11858 %)
Profit	(49.0m)	(97.1m)	(84.7m)	(88.4m)	(58.8m)	(137m)	(173m)
% profit margin	(599 %)	(2201 %)	124578 %	(20762 %)	(188 %)	(549 %)	(17021 %)
EV / revenue	51.0x	82.3x	-10254.4x	1101.6x	14.7x	10.7x	374.2x
EV / EBITDA	-7.7x	-4.2x	-8.2x	-6.2x	-4.7x	-2.4x	-3.2x
R&D budget	49.8m	74.5m	70.5m	65.8m	-	-	-
R&D % of revenue	608 %	1690 %	(103732 %)	15446 %	-	-	-

Date	Investors	Amount	Round
Jan 1997	University College London	N/A	Spinout
Oct 2005	N/A	N/A	IPO
Feb 2015	Truffle Capital HealthCap Redmont Capital Novartis Venture Fund	$16.0m	Post IPO Equity
Aug 2017	Truffle Capital HealthCap Redmont Capital Novartis Venture Fund	$14.7m	Post IPO Equity
Sep 2018	N/A	$17.0m	Post IPO Equity
Aug 2019	ASPR Biomedical Advanced Research and Development Authority (BARDA)	$3.7m	Grant
Total Funding		$3.7m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Altimmune Jan 2017

Immune Targeting Systems

ACQUISITION by Altimmune Feb 2015